© 1998 by Oxford University Press
Journal Of The National Cancer Institute, Vol 90, 1473-1479, Copyright © 1998 by Oxford University Press
JG Cairncross, K Ueki, MC Zlatescu, DK Lisle, DM Finkelstein, RR Hammond, JS Silver, PC Stark, DR Macdonald, Y Ino, DA Ramsay and DN Louis
BACKGROUND/METHODS: Gliomas are common malignant neoplasms of the central
nervous system. Among the major subtypes of gliomas, oligodendrogliomas are
distinguished by their remarkable sensitivity to chemotherapy, with
approximately two thirds of anaplastic (malignant) oligodendrogliomas
responding dramatically to combination treatment with procarbazine,
lomustine, and vincristine (termed PCV). Unfortunately, no clinical or
pathologic feature of these tumors allows accurate prediction of their
response to chemotherapy. Anaplastic oligodendrogliomas also are
distinguished by a unique constellation of molecular genetic alterations,
including coincident loss of chromosomal arms 1p and 19q in 50%-70% of
tumors. We have hypothesized that these or other specific genetic changes
might predict the response to chemotherapy and prognosis in patients with
anaplastic oligodendrogliomas. Therefore, we have analyzed molecular
genetic alterations involving chromosomes 1p, 10q, and 19q and the TP53 (on
chromosome 17p) and CDKN2A (on chromosome 9p) genes, in addition to
clinicopathologic features in 39 patients with anaplastic
oligodendrogliomas for whom chemotherapeutic response and survival could be
assessed. RESULTS/CONCLUSIONS: Allelic loss (or loss of heterozygosity) of
chromosome 1p is a statistically significant predictor of chemosensitivity,
and combined loss involving chromosomes 1p and 19q is statistically
significantly associated with both chemosensitivity and longer
recurrence-free survival after chemotherapy. Moreover, in both univariate
and multivariate analyses, losses involving both chromosomes 1p and 19q
were strongly associated with longer overall survival, whereas CDKN2A gene
deletions and ring enhancement (i.e., contrast enhancement forming a rim
around the tumor) on neuroimaging were associated with a significantly
worse prognosis. The inverse relationship between CDKN2A gene deletions and
losses of chromosomes 1p and 19q further implies that these differential
clinical behaviors reflect two independent genetic subtypes of anaplastic
oligodendroglioma. These results suggest that molecular genetic analysis
may aid therapeutic decisions and predict outcome in patients with
anaplastic oligodendrogliomas.
ARTICLES
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
Department of Medical and Experimental Oncology, London Regional Cancer Centre, Ontario, Canada.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Snuderl, A. F. Eichler, K. L. Ligon, Q. U. Vu, M. Silver, R. A. Betensky, A. H. Ligon, P. Y. Wen, D. N. Louis, and A. J. Iafrate Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss Clin. Cancer Res., October 15, 2009; 15(20): 6430 - 6437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Moore, K. M. Holmes, S. M. Smith, Y. Wu, E. Tchougounova, L. Uhrbom, R. Sawaya, J. M. Bruner, G. N. Fuller, and W. Zhang IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas PNAS, September 29, 2009; 106(39): 16675 - 16679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mahajan and R. A. Prayson Repeated Molecular Testing in Gliomas: A Retrospective Study of 53 Cases Am J Clin Pathol, July 1, 2009; 132(1): 118 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors Neurology, May 5, 2009; 72(18): 1601 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. C. Bromberg and M. J. van den Bent Oligodendrogliomas: Molecular Biology and Treatment Oncologist, February 1, 2009; 14(2): 155 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sivasankaran, M. Degen, A. Ghaffari, M. E. Hegi, M.-F. Hamou, M.-C. S. Ionescu, C. Zweifel, M. Tolnay, M. Wasner, S. Mergenthaler, et al. Tenascin-C Is a Novel RBPJ{kappa}-Induced Target Gene for Notch Signaling in Gliomas Cancer Res., January 15, 2009; 69(2): 458 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ducray, E. Criniere, A. Idbaih, K. Mokhtari, Y. Marie, S. Paris, S. Navarro, F. Laigle-Donadey, C. Dehais, J. Thillet, et al. {alpha}-Internexin expression identifies 1p19q codeleted gliomas Neurology, January 13, 2009; 72(2): 156 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neuro-oncol, January 1, 2009; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Lassman Management of Newly Diagnosed Anaplastic Oligodendrogliomas ASCO Educational Book, January 1, 2009; 2009(1): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.E. Emblem, D. Scheie, P. Due-Tonnessen, B. Nedregaard, T. Nome, J.K. Hald, K. Beiske, T.R. Meling, and A. Bjornerud Histogram Analysis of MR Imaging-Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes AJNR Am. J. Neuroradiol., October 1, 2008; 29(9): 1664 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Idbaih, E. Criniere, Y. Marie, A. Rousseau, K. Mokhtari, M. Kujas, Y. El Houfi, C. Carpentier, S. Paris, B. Boisselier, et al. Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas Neuro-oncol, August 1, 2008; 10(4): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]
|
|
|
|
|
|
W. P. Mason and J. G. Cairncross Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas Neurology, July 29, 2008; 71(5): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Colman and K. Aldape Molecular Predictors in Glioblastoma: Toward Personalized Therapy Arch Neurol, July 1, 2008; 65(7): 877 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kato, J. Shinoda, N. Nakayama, K. Miwa, A. Okumura, H. Yano, S. Yoshimura, T. Maruyama, Y. Muragaki, and T. Iwama Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline Positron-Emission Tomography AJNR Am. J. Neuroradiol., June 1, 2008; 29(6): 1176 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Law, R. J. Young, J. S. Babb, N. Peccerelli, S. Chheang, M. L. Gruber, D. C. Miller, J. G. Golfinos, D. Zagzag, and G. Johnson Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Radiology, May 1, 2008; 247(2): 490 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Brown, M. Zlatescu, A. Sijben, G. Roldan, J. Easaw, P. Forsyth, I. Parney, R. Sevick, E. Yan, D. Demetrick, et al. The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma Clin. Cancer Res., April 15, 2008; 14(8): 2357 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.W. Henson, S. Ulmer, and G.J. Harris Brain Tumor Imaging in Clinical Trials AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kaloshi, S. Everhard, F. Laigle-Donadey, Y. Marie, S. Navarro, K. Mokhtari, A. Idbaih, F. Ducray, J. Thillet, K. Hoang-Xuan, et al. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri Neurology, February 19, 2008; 70(8): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shirahata, K. Iwao-Koizumi, S. Saito, N. Ueno, M. Oda, N. Hashimoto, J. A. Takahashi, and K. Kato Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis Clin. Cancer Res., December 15, 2007; 13(24): 7341 - 7356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The German Glioma Network, M. Weller, H. Berger, C. Hartmann, J. Schramm, M. Westphal, M. Simon, R. Goldbrunner, D. Krex, J. P. Steinbach, et al. Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? Clin. Cancer Res., December 1, 2007; 13(23): 6933 - 6937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wohlfahrt, B. C. Beard, A. Lieber, and H.-P. Kiem A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models Cancer Res., September 15, 2007; 67(18): 8783 - 8790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Abrey, D. N. Louis, N. Paleologos, A. B. Lassman, J. J. Raizer, W. Mason, J. Finlay, D. R. MacDonald, L. M. DeAngelis, J. G. Cairncross, et al. Survey of treatment recommendations for anaplastic oligodendroglioma Neuro-oncol, July 1, 2007; 9(3): 314 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney, R. Baumber, R. Parsons, K. R. Lamborn, M. S. Berger, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro-oncol, July 1, 2007; 9(3): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hong, K. S. Moorefield, P. Jun, K. D. Aldape, S. Kharbanda, H. S. Phillips, and J. F. Costello Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth PNAS, June 26, 2007; 104(26): 10974 - 10979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Wen and L. M. DeAngelis Chemotherapy for low-grade gliomas: Emerging consensus on its benefits Neurology, May 22, 2007; 68(21): 1762 - 1763. [Full Text] [PDF]
|
|
|
|
|
|
G. Kaloshi, A. Benouaich-Amiel, F. Diakite, S. Taillibert, J. Lejeune, F. Laigle-Donadey, M.-A Renard, W. Iraqi, A. Idbaih, S. Paris, et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome Neurology, May 22, 2007; 68(21): 1831 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-T B. Ngo, T. Peng, X.-J. Liang, O. Akeju, S. Pastorino, W. Zhang, Y. Kotliarov, J. C. Zenklusen, H. A. Fine, D. Maric, et al. The 1p-Encoded Protein Stathmin and Resistance of Malignant Gliomas to Nitrosoureas J Natl Cancer Inst, April 18, 2007; 99(8): 639 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lavon, D. Zrihan, B. Zelikovitch, Y. Fellig, D. Fuchs, D. Soffer, and T. Siegal Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas Clin. Cancer Res., March 1, 2007; 13(5): 1429 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Spampinato, J. K. Smith, L. Kwock, M. Ewend, J. D. Grimme, D. L. A. Camacho, and M. Castillo Cerebral Blood Volume Measurements and Proton MR Spectroscopy in Grading of Oligodendroglial Tumors Am. J. Roentgenol., January 1, 2007; 188(1): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Miller, C. P. Dunham, B. W. Scheithauer, and A. Perry Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas J. Clin. Oncol., December 1, 2006; 24(34): 5419 - 5426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Jenkins, H. Blair, K. V. Ballman, C. Giannini, R. M. Arusell, M. Law, H. Flynn, S. Passe, S. Felten, P. D. Brown, et al. A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. Cancer Res., October 15, 2006; 66(20): 9852 - 9861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al. Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study J. Clin. Oncol., October 10, 2006; 24(29): 4746 - 4753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jeuken, S. Cornelissen, S. Boots-Sprenger, S. Gijsen, and P. Wesseling Multiplex Ligation-Dependent Probe Amplification: A Diagnostic Tool for Simultaneous Identification of Different Genetic Markers in Glial Tumors J. Mol. Diagn., September 1, 2006; 8(4): 433 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Engler, G. Mohapatra, D. N. Louis, and R. A. Betensky A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations Biostat., July 1, 2006; 7(3): 399 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Jenkinson, D. G. du Plessis, T. S. Smith, K. A. Joyce, P. C. Warnke, and C. Walker Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features Brain, July 1, 2006; 129(7): 1884 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Gilbert and F. F. Lang Anaplastic Oligodendroglial Tumors: A Tale of Two Trials J. Clin. Oncol., June 20, 2006; 24(18): 2689 - 2690. [Full Text] [PDF]
|
|
|
|
|
|
G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre, et al. Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J. Clin. Oncol., June 20, 2006; 24(18): 2707 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J.B. Taphoorn, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, et al. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial J. Clin. Oncol., June 20, 2006; 24(18): 2715 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors Neurology, June 13, 2006; 66(11): 1661 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Grier and T. Batchelor Low-grade gliomas in adults. Oncologist, June 1, 2006; 11(6): 681 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mohapatra, R. A. Betensky, E. R. Miller, B. Carey, L. D. Gaumont, D. A. Engler, and D. N. Louis Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue: Array Comparative Genomic Hybridization Correlates with Loss of Heterozygosity and Fluorescence in Situ Hybridization J. Mol. Diagn., May 1, 2006; 8(2): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Abrey, B. H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, D. Salzman, J. L. Finlay, S. Gardner, K. Peterson, W. Hu, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up Neuro-oncol, April 1, 2006; 8(2): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Lang and M. R. Gilbert Diffusely Infiltrative Low-Grade Gliomas in Adults J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response J. Clin. Oncol., March 10, 2006; 24(8): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hata, K. Yoshimoto, N. Yokoyama, M. Mizoguchi, T. Shono, Y. Guan, T. Tahira, Y. Kukita, K. Higasa, S. Nagata, et al. Allelic Losses of Chromosome 10 in Glioma Tissues Detected by Quantitative Single-Strand Conformation Polymorphism Analysis Clin. Chem., March 1, 2006; 52(3): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, T. Rice, R. Miike, A. McMillan, K. R. Lamborn, K. Aldape, and M. D. Prados Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area Neuro-oncol, January 1, 2006; 8(1): 12 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. French, S. M.A. Swagemakers, J. H.A. Nagel, M. C.M. Kouwenhoven, E. Brouwer, P. van der Spek, T. M. Luider, J. M. Kros, M. J. van den Bent, and P. A. Sillevis Smitt Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas Cancer Res., December 15, 2005; 65(24): 11335 - 11344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Hamstra, T. L. Chenevert, B. A. Moffat, T. D. Johnson, C. R. Meyer, S. K. Mukherji, D. J. Quint, S. S. Gebarski, X. Fan, C. I. Tsien, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma PNAS, November 15, 2005; 102(46): 16759 - 16764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koeller and E. J. Rushing From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation RadioGraphics, November 1, 2005; 25(6): 1669 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yuan, K. Choi, C. Khosla, X. Zheng, R. Higashikubo, M. R. Chicoine, and K. M. Rich Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas Mol. Cancer Ther., September 1, 2005; 4(9): 1293 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Misra, M. Pellarin, J. Nigro, I. Smirnov, D. Moore, K. R. Lamborn, D. Pinkel, D. G. Albertson, and B. G. Feuerstein Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma Clin. Cancer Res., April 15, 2005; 11(8): 2907 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alaminos, V. Davalos, S. Ropero, F. Setien, M. F. Paz, M. Herranz, M. F. Fraga, J. Mora, N.-K. V. Cheung, W. L. Gerald, et al. EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma Cancer Res., April 1, 2005; 65(7): 2565 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Nutt, R. A. Betensky, M. A. Brower, T. T. Batchelor, D. N. Louis, and A. O. Stemmer-Rachamimov YKL-40 Is a Differential Diagnostic Marker for Histologic Subtypes of High-Grade Gliomas Clin. Cancer Res., March 15, 2005; 11(6): 2258 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. DeAngelis Chemotherapy for Brain Tumors -- A New Beginning N. Engl. J. Med., March 10, 2005; 352(10): 1036 - 1038. [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Fisher and P. A. Buffler Malignant Gliomas in 2005: Where to GO From Here? JAMA, February 2, 2005; 293(5): 615 - 617. [Full Text] [PDF]
|
|
|
|
|
|
S. Cha, T. Tihan, F. Crawford, N. J. Fischbein, S. Chang, A. Bollen, S. J. Nelson, M. Prados, M. S. Berger, and W. P. Dillon Differentiation of Low-Grade Oligodendrogliomas from Low-Grade Astrocytomas by Using Quantitative Blood-Volume Measurements Derived from Dynamic Susceptibility Contrast-Enhanced MR Imaging AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 266 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Barbashina, P. Salazar, E. C. Holland, M. K. Rosenblum, and M. Ladanyi Allelic Losses at 1p36 and 19q13 in Gliomas: Correlation with Histologic Classification, Definition of a 150-kb Minimal Deleted Region on 1p36, and Evaluation of CAMTA1 as a Candidate Tumor Suppressor Gene Clin. Cancer Res., February 1, 2005; 11(3): 1119 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Doolittle, L. E. Abrey, W. A. Bleyer, S. Brem, T. P. Davis, P. Dore-Duffy, L. R. Drewes, W. A. Hall, J. M. Hoffman, A. Korfel, et al. New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting Clin. Cancer Res., January 15, 2005; 11(2): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Voloschin, D. N. Louis, G. R. Cosgrove, and T. T. Batchelor Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study Neuro-oncol, January 1, 2005; 7(1): 97 - 100. [Abstract] [PDF]
|
|
|
|
|
|
A. B. Heimberger, E. C. McGary, D. Suki, M. Ruiz, H. Wang, G. N. Fuller, and M. Bar-Eli Loss of the AP-2{alpha} Transcription Factor Is Associated with the Grade of Human Gliomas Clin. Cancer Res., January 1, 2005; 11(1): 267 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Laigle-Donadey, N. Martin-Duverneuil, J. Lejeune, E. Criniere, L. Capelle, H. Duffau, P. Cornu, P. Broet, M. Kujas, K. Mokhtari, et al. Correlations between molecular profile and radiologic pattern in oligodendroglial tumors Neurology, December 28, 2004; 63(12): 2360 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Higuchi, Y. Iwadate, and A. Yamaura Treatment of low-grade oligodendroglial tumors without radiotherapy Neurology, December 28, 2004; 63(12): 2384 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Korshunov, R. Sycheva, and A. Golanov Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence In situ Hybridization Clin. Cancer Res., December 1, 2004; 10(23): 7820 - 7826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Cairncross Imaging Molecular Signatures in Oligodendroglioma: Commentary on Walker et al., pages 7182-7191 Clin. Cancer Res., November 1, 2004; 10(21): 7109 - 7111. [Full Text] [PDF]
|
|
|
|
|
|
C. Walker, D. G. du Plessis, D. Fildes, B. Haylock, D. Husband, M. D. Jenkinson, K. A. Joyce, J. Broome, K. Kopitski, J. Prosser, et al. Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component Clin. Cancer Res., November 1, 2004; 10(21): 7182 - 7191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Eskandar, J. S. Loeffler, A. M. O'Neill, G. J. Hunter, and D. N. Louis Case 33-2004 - A 34-Year-Old Man with a Seizure and a Frontal-Lobe Brain Lesion N. Engl. J. Med., October 28, 2004; 351(18): 1875 - 1882. [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakahara, T. Shiraishi, H. Okamoto, T. Mineta, T. Oishi, K. Sasaki, and K. Tabuchi Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization Neuro-oncol, October 1, 2004; 6(4): 281 - 289. [Abstract] [PDF]
|
|
|
|
|
|
W. K. Pfisterer, N. C. Hank, M. C. Preul, W. P. Hendricks, J. Pueschel, S. W. Coons, and A. C. Scheck Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas Neuro-oncol, October 1, 2004; 6(4): 290 - 299. [Abstract] [PDF]
|
|
|
|
|
|
P. Birner, M. Preusser, E. Gelpi, J. Berger, B. Gatterbauer, I. M. Ambros, P. F. Ambros, T. Acker, K. H. Plate, A. L. Harris, et al. Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications Clin. Cancer Res., October 1, 2004; 10(19): 6567 - 6571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Freije, F. E. Castro-Vargas, Z. Fang, S. Horvath, T. Cloughesy, L. M. Liau, P. S. Mischel, and S. F. Nelson Gene Expression Profiling of Gliomas Strongly Predicts Survival Cancer Res., September 15, 2004; 64(18): 6503 - 6510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al. Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chamberlain Gliomatosis cerebri: Better definition, better treatment Neurology, July 27, 2004; 63(2): 204 - 205. [Full Text] [PDF]
|
|
|
|
|
|
M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, H. Gervais, F. Laigle, A. Carpentier, K. Mokhtari, et al. Initial chemotherapy in gliomatosis cerebri Neurology, July 27, 2004; 63(2): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al. Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations Cancer Res., July 1, 2004; 64(13): 4648 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Megyesi, E. Kachur, D. H. Lee, M. C. Zlatescu, R. A. Betensky, P. A. Forsyth, Y. Okada, H. Sasaki, M. Mizoguchi, D. N. Louis, et al. Imaging Correlates of Molecular Signatures in Oligodendrogliomas Clin. Cancer Res., July 1, 2004; 10(13): 4303 - 4306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V P Collins Brain tumours: classification and genes J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii2 - ii11. [Full Text] [PDF]
|
|
|
|
|
|
R Rampling, A James, and V Papanastassiou The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii24 - ii30. [Full Text] [PDF]
|
|
|
|
|
|
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas J. Clin. Oncol., May 15, 2004; 22(10): 1926 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T J M Hulsebos, D Troost, and S Leenstra Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 723 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Brat, W. F. Seiferheld, A. Perry, E. H. Hammond, K. J. Murray, A. R. Schulsinger, M. P. Mehta, and W. J. Curran Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials Neuro-oncol, April 1, 2004; 6(2): 96 - 103. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, J. Vredenburgh, J. H. Sampson, J. M. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma Neuro-oncol, April 1, 2004; 6(2): 134 - 144. [Abstract] [PDF]
|
|
|
|
|
|
M. Wang, K. M. Murphy, P. Kulesza, K. J. Hatanpaa, A. Olivi, A. Tufaro, Y. Erozan, W. H. Westra, P. C. Burger, and K. D. Berg Molecular Diagnosis of Metastasizing Oligodendroglioma: A Case Report J. Mol. Diagn., February 1, 2004; 6(1): 52 - 57. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. M. Johnson, C. R. Bradford, S. B. Gruber, V. K. Sondak, and J. L. Schwartz Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma: Update of Current Concepts Arch Dermatol, January 1, 2004; 140(1): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stupp and B. G. Baumert Promises and controversies in the management of low-grade glioma Ann. Onc., December 1, 2003; 14(12): 1695 - 1696. [Full Text] [PDF]
|
|
|
|
|
|
A. Pace, A. Vidiri, E. Galie, M. Carosi, S. Telera, A. M. Cianciulli, P. Canalini, D. Giannarelli, B. Jandolo, and C. M. Carapella Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response Ann. Onc., December 1, 2003; 14(12): 1722 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hong, A. W. Bollen, and J. F. Costello The Contribution of Genetic and Epigenetic Mechanisms to Gene Silencing in Oligodendrogliomas Cancer Res., November 15, 2003; 63(22): 7600 - 7605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shinojima, K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. Makino, H. Saya, H. Hirano, J.-i. Kuratsu, et al. Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme Cancer Res., October 15, 2003; 63(20): 6962 - 6970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Walker, D. G. du Plessis, K. A. Joyce, Y. Machell, J. Thomson-Hehir, S. A. Al Haddad, J. C. Broome, and P. C. Warnke Phenotype versus Genotype in Gliomas Displaying Inter- or Intratumoral Histological Heterogeneity Clin. Cancer Res., October 15, 2003; 9(13): 4841 - 4851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tada, M. Kochi, H. Saya, J.-i. Kuratsu, S. Shiraishi, T. Kamiryo, N. Shinojima, and Y. Ushio Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1 Neuro-oncol, October 1, 2003; 5(4): 228 - 234. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Vos, O. S. Hoekstra, F. Barkhof, J. Berkhof, J. J. Heimans, C. J. van Groeningen, W. P. Vandertop, B. J. Slotman, and T. J. Postma Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma J. Clin. Oncol., October 1, 2003; 21(19): 3559 - 3565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Backlund, B. R. Nilsson, H. M. Goike, E. E. Schmidt, L. Liu, K. Ichimura, and V. P. Collins Short Postoperative Survival for Glioblastoma Patients with a Dysfunctional Rb1 Pathway in Combination with No Wild-type PTEN Clin. Cancer Res., September 15, 2003; 9(11): 4151 - 4158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schiff and M. Sanson Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri Neurology, August 12, 2003; 61(3): 425 - 425. [Full Text] [PDF]
|
|
|
|
|
|
A. Perry Pathology of low-grade gliomas: An update of emerging concepts Neuro-oncol, July 1, 2003; 5(3): 168 - 178. [Abstract] [PDF]
|
|